Healthcare

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

Mesoblast develops cell therapies derived from donor mesenchymal stem cells, designed to treat a range of inflammatory and immune-mediated conditions where the body's own immune response contributes to disease progression. The company's pipeline has targeted conditions including graft-versus-host disease in transplant patients, heart failure …

Cogstate provides cognitive assessment technology and services used by pharmaceutical companies to measure cognitive function as an endpoint in clinical trials, particularly for drugs targeting neurological and psychiatric conditions such as Alzheimer's disease, depression and other cognitive or mood-related disorders. The company's testing platform …

Telix Pharmaceuticals Ltd (ASX:TLX) closed lower on 8 July 2026, with shares declining 1.84% to AUD 16.58. The latest move extends a challenging period for the stock, which remains down 31.03% over the past year.

After enduring a challenging year,CSL Ltd (ASX: CSL)is beginning to regain investor attention. The healthcare giant closed atAUD 124.30, with shares climbing26.95% over the past month, signalling renewed confidence after a prolonged period of weakness.

4DMEDICAL has developed XV Technology, a functional lung imaging system that uses MRI to create detailed functional maps of lung ventilation and perfusion. This technology provides physicians with information about how air and blood flow through the lungs in real time, going beyond anatomical …